PORTLAND, OR--(Marketwired - Dec 15, 2014) - Cromos™ Pharma, an international full-service CRO announced today the implementation of a risk-sharing platform partnering with biotech, pharma and device companies that have promising drug, biologics or medical device technologies. Cromos™ Pharma offers several unique business partnership algorithms through its risk-sharing model, including clinical research program conduct in exchange for equity or licensing opportunities.
"I have been intimately involved in the formation of a biotechnology company and understand how difficult it is to raise sufficient funds even for the most exciting and ground-breaking medical discoveries," said Dr. Vlad Bogin, Cromos™ Pharma's CEO. "Cromos™ Pharma has experienced steady and sustained growth and is now positioned to offer companies with promising clinical programs mutually beneficial partnership algorithms."
"Over the years we have been approached by a number of biotech companies with compelling technologies," said Dr. Andrey Tarakanov, company's Managing Director. "Cromos™ Pharma's team would be asked to develop a trial protocol or perform a feasibility study, but then the process would stall due to company's financial constraints."
"We want to change this paradigm and help the companies advance the science we believe in," continued Dr. Bogin. "Cromos™ Pharma's team is expert in clinical research, biopharmacology and medicine -- this expertise and our state of the art facilities uniquely position Cromos Pharma to accurately evaluate medical technologies and select the best partners. We invite interested pharmaceutical, biotech, and medical device companies to reach out to us for an in depth evaluation of potential strategic partnerships."
About Cromos™ Pharma, LLC
Cromos™ Pharma, LLC is a contract research organization (CRO) with operations in the post-Soviet space and in Eastern/Central Europe. The company provides a full spectrum of trial-related services which include regulatory approvals, medical writing, feasibility assessments, monitoring, project management and warehousing. Cromos™ Pharma, LLC is a privately owned company.
Cromos Pharma is delighted to be taking part in the upcoming DIA Europe conference (15 – 19 March 2021) and BIO-Europe Spring (22-25 March 2021).
February 11th is International Women and Girls in Science Day. A joint UNESCO and UN-Women initiative, it aims to promote the role of #WomenInScience and to challenge some of the barriers to girls pursuing a career in science.
Are you a sponsor seeking to conduct clinical trials in the European Union but do not have a registered office in the European Economic Area? If so, in order to comply with the European Union Clinical Trial Directive, you are required to work with a Legal Representative registered in an EEA country.
Each 4th February, #WorldCancerDay aims to raise awareness of the global personal, social and economic burden of cancer. World Cancer Day was established in Paris at the first World Cancer Summit in 2000.
As 2021 begins, many countries are grappling with a renewed surge of COVID-19 infections necessitating further public health restrictions putting more pressure on health systems, societies and global economies. The task of rolling out approved vaccines is increasingly urgent. Almost 16 million doses of COVID-19 vaccines have been administered to date in 37 countries worldwide according to data compiled by Bloomberg ( updated 7 Jan 2021).
Tuesday 1 December marked World AIDS Day 2020. Although throughout this year our focus has been on the coronavirus pandemic, World AIDS Day is an opportunity to reflect on another pandemic where a virus passed from animals to humans with devastating consequences. To date 77 million people worldwide have been infected with HIV. In spite of innovative new treatments 35 million people have died from the virus.
If you missed the live webinar “Where in the world should I locate my pivotal clinical trial?” you can now watch the recording by clicking here. The webinar hosted by the Society of Physician Entrepreneurs (SoPE) and Workforce Genetics features Cromos Pharma's CEO Vlad Bogin, M.D, FACP.